Michael J. Roberts, Ph.D.

Co-Founder and CEO

Dr. Roberts has 25+ years of pharmaceutical research, development, corporate development, and executive experience. He is co-founder and CEO of Centaur Bio. Prior to Centaur he was co-founder and Acting CEO of Corino Therapeutics. Dr. Roberts led and ran all activities related to Corino and the development of CRX-1008 in ATTR. He is a pharmaceutical and biotech consultant and owner of MAC B Consulting. Prior to Corino, Dr. Roberts was VP, Business Development and Corporate Officer of publicly traded Chelsea Therapeutics, Inc. He was responsible for business development efforts focused primarily on licensing and M&A with consideration to pipeline management. He led the sale of Chelsea Therapeutics to H. Lundbeck A/S in 2014 for $658M. Prior to Chelsea Therapeutics, Dr. Roberts was Director of Business Development for their Nektar Therapeutics’ Molecule Engineering technology and completed a number of transactions with large and specialty pharmaceutical companies. Dr. Roberts has completed pharmaceutical transactions valued at over $1B. Prior to this he was Manager of Biopharmaceutical Research at Shearwater Corporation where he led and was successful in the development of preclinical drug candidates from initial stages of research through Phase I clinical study, including inventing the product Movantik™, a treatment for opioid-induced constipation, subsequently licensed to AstraZeneca in a billion-dollar deal. Shearwater was sold to Inhale Therapeutic Systems (ie. Nektar Therapeutics) in 2001 for $200M.
Dr. Roberts obtained his Ph.D. in Materials Science from the University of Alabama and B.S. in Chemical Engineering from Pennsylvania State University.

Simon Pedder, Ph.D.

Executive Chairman

Simon has a career of over 30 years in drug development and commercialization. He was recently Chief Executive Officer of Nirogy. Prior he had leadership roles as; Chief Business and Strategy Officer for Athenex; President and CEO of Cellectar Biosciences; President and CEO of Chelsea Therapeutics; Global Vice President of Oncology Pharma Business and Executive Officer at Hoffmann-LaRoche. Previous positions at Roche included Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of Hepatitis Franchise. Prior, he was Clinical Leader for a number of development compounds at Roche. He has been on a number of both private and public Boards.
Early in his career he was a faculty in the Department of Pharmacology in College of Medicine at the University of Saskatchewan, where he obtained his Ph.D. in Clinical Pharmacology. During his longstanding career in pharmaceutical development, Simon had played key roles in the successful development and commercial of multiple proprietary pharmaceutical products including Tasmar®, Pegasys®, Copegus®, Northera® and Klisyri®. In addition to his Ph.D., Simon obtained a Master of Science in Toxicology from Concordia University, a Joint Honors Bachelor degree in Environmental Studies/Biology from the University of Waterloo, and he completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.

Timothy L. Maness, CPA

Chief Financial Officer

Mr. Maness has 20 years of experience in senior financial roles in the pharmaceutical industry with over 35+ years of experience in various industries. Mr. Maness currently provides consulting services to a variety of life sciences clients, both public and private, in areas including, but not limited to, IPO readiness assessments, general accounting and finance support, SEC reporting and compliance, Sarbanes-Oxley program development for internal control activities, internal audit and interim CFO roles. In 2019, acting as an interim CFO, Mr. Maness led a successful US IPO for a Canadian-based life sciences company and remains active in the public and private equity arenas for life sciences. Prior to operating his consulting business, Mr. Maness served as the Chief Financial Officer of Ballantyne Therapeutics, Inc. (now Corino Therapeutics), a pharmaceutical company, from May 2015 to April 2016. From 2006 to 2014, Mr. Maness served as the Senior Director of Finance and Corporate Controller at Chelsea Therapeutics International Inc. until the sale of the company to Lundbeck, Inc. Prior to Chelsea Therapeutics, Mr. Maness provided consulting services and held a variety of senior financial management roles, primarily in software and technology services. Mr. Maness received a B.S. in Accounting from the University of North Carolina at Charlotte and is licensed as a Certified Public Accountant and as a Chartered Global Management Accountant.

L. Arthur Hewitt, Ph.D.

Chief Development Officer

To come